TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A MedPage Today opinion article by South Asian physician Hamayle Saeed describes being screened for diabetes at a BMI of 23 but denied a GLP-1 weight-loss drug at BMI 26.5 because she did not meet standard eligibility thresholds. Saeed argues that Asian-specific diabetes and obesity risk measures have not been reflected in coverage rules, though individual coverage decisions and policy changes vary.
South Asian physician Hamayle Saeed says she was screened for diabetes once her BMI passed 23, but was denied a GLP-1 medication at a BMI of 26.5 because she had neither diabetes nor the BMI level commonly used for weight-loss drug eligibility. In a MedPage Today opinion article published Oct. 31, 2026, Saeed argues that the contrast reflects a gap between Asian-specific risk guidance and insurer access rules.
Saeed writes that the American Diabetes Association’s guidance prompted diabetes screening at a BMI of 23 for her as an Asian American. She says a request for a GLP-1 receptor agonist was denied because she was below the usual BMI 30 threshold, and below BMI 27 with a weight-related condition. She reports having a BMI of 26.5 and no diabetes. Her account describes her own experience; the article does not identify the insurer or provide the denial letter.
The article places that experience alongside changes in clinical guidance and coverage. Saeed says the ADA issued Asian-specific waist and BMI thresholds for diagnosing obesity in June 2026, while California’s Medi-Cal program dropped coverage for GLP-1 drugs prescribed for weight loss in January and Massachusetts’ MassHealth followed in July. The article does not detail every plan’s rules or establish that those state changes caused her individual denial.
Saeed also cites a 2026 analysis of 352 GLP-1 trials, saying BMI cutoffs excluded a larger share of Asian participants than other eligibility criteria. According to her summary, a BMI cutoff of 30 made 13.5% of Asian American adults and 7.2% of Korean adults eligible, compared with 41.5% of non-Asian American adults. Those figures concern eligibility under the analyzed trial criteria, not treatment outcomes or insurance approvals.
The Gap Between Risk and Coverage
The issue Saeed raises is whether a single BMI threshold can fairly guide both medical risk assessment and access to treatment across populations. If clinicians screen Asian patients at lower BMIs because diabetes risk can emerge at lower weights, but coverage systems rely on higher thresholds, some patients may be identified as at risk before they qualify for a medication under standard rules.
That distinction matters to patients and prescribers, but it does not by itself establish that GLP-1 treatment is appropriate for every person below BMI 30. Eligibility depends on the drug’s approved indication, a patient’s health circumstances, clinical judgment, and the insurer’s policy. Saeed’s argument is that coverage criteria may not reflect the risk thresholds used in care, potentially leaving certain patients with fewer covered options.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Fitbit Sense 2 Health and Fitness Smartwatch (Lunar White/Platinum)
BowFlex Results Series SelectTech Adjustable Dumbbells (Pair)
As an affiliate, we earn on qualifying purchases.
Why Asian BMI Thresholds Differ
Saeed says people of Asian descent may have more visceral fat and less muscle at the same BMI than people of European descent, and that this body composition is associated with insulin resistance. She cites World Health Organization action points of BMI 23 and 27.5 for Asian populations, lower than conventional thresholds used in many U.S. settings. These are population-level risk measures; they do not diagnose an individual on their own.
The opinion also cites a study of nearly 1.5 million adults in England. Researchers estimated that diabetes risk reached the level associated with BMI 30 among white adults at BMI 23.9 for South Asian adults and 26.9 for Chinese adults. Saeed contrasts such findings with the BMI values commonly appearing in trial criteria and payer forms. She says current U.S. drug labels describe eligible adults using obesity or overweight plus a weight-related condition, while numeric cutoffs remain prominent in trial descriptions and coverage paperwork.
As further evidence, Saeed points to the 2025 STEP 11 study in South Korea and Thailand, which used a local obesity threshold of BMI 25. She reports that participants receiving semaglutide lost 16% of body weight, compared with 3.1% among those receiving placebo. A post hoc analysis of 68 participants who began below BMI 30 found losses of 17.6% among 45 semaglutide recipients and 4.4% among 23 placebo recipients. The study findings she cites do not establish coverage eligibility or settle what thresholds U.S. insurers should apply.
“The ADA guideline that flags me for annual diabetes screening and the prior authorization form that denies me the drug are describing the same 26.5. Only one of them was written with an Asian body in mind.”
— Hamayle Saeed, MD, in a MedPage Today opinion article
How Coverage Rules Will Change
The opinion article does not identify the insurer that denied Saeed’s request, reproduce its rationale, or say whether she appealed. It is also unclear how widely the screening and coverage mismatch described in her case occurs, since plans may use different criteria and apply them differently.
The source reports clinical guidance, trial findings, and state coverage changes, but those details do not show that every Asian patient below BMI 30 is eligible for or would benefit from a GLP-1 drug. The article also does not establish whether the cited trial results will prompt changes to U.S. insurer policies. Coverage remains plan-specific, and the effect of the ADA’s updated thresholds on prior authorization decisions is not yet clear.
Whether Payers Revise Their Criteria
The next practical developments are likely to come through insurer and public-program coverage policies, prior authorization forms, and how clinicians apply updated ADA guidance. Saeed’s article calls attention to the difference between those clinical standards and the numeric thresholds commonly used in coverage decisions; it does not announce a specific policy change or timetable.
For patients seeking treatment, the relevant next step depends on their own clinician and plan. They can ask how the plan defines eligibility, what documentation it requires, and whether an appeal is available. Any future changes to drug labeling or coverage would need to be assessed separately from the risk thresholds discussed in the opinion.
Key Questions
What happened in the report?
South Asian physician Hamayle Saeed wrote in MedPage Today that she was screened for diabetes at a BMI above 23 but denied a GLP-1 medication at BMI 26.5 because she did not meet the thresholds applied to her request.
Why does the article focus on BMI 23?
Saeed says diabetes screening guidance uses a lower BMI threshold for Asian Americans because diabetes risk can occur at lower weights. A screening threshold is not the same as a medication coverage threshold.
Does a BMI below 30 automatically qualify someone for a GLP-1?
No. Eligibility depends on the medication’s indication, a person’s health circumstances, clinical judgment, and their insurer’s rules. The article describes one physician’s reported denial and a broader policy concern; it does not establish universal eligibility.
What remains unknown about Saeed’s denial?
The article does not name the insurer, provide its written decision, or say whether Saeed appealed. It also does not show how common the same circumstances are across health plans.
Source: medpagetoday.com
